Active Biotech gets Positive Clinical Results in Prostate Cancer Project TASQ

An interim analysis of Active Biotech AB's ongoing TASQ Phase I study shows a treatment effect for all evaluated prostate cancer patients.

The Phase I study comprises a total of 24 patients with so called hormone refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen, PSA, which is a surrogate marker for tumor progression.

The current interim analysis was made after ten patients had passed four months of TASQ treatment. Treatment with 0.5 mg TASQ daily led to a reduced rate of PSA increase for all ten patients. In nine out of ten patients this decrease was larger than 50%. Four out of the ten patients showed a decreased serum level of PSA after four months TASQ treatment.

The results also showed that treatment with TASQ was well tolerated with only mild and transient side-effects.

The study is being conducted in the urology clinics at the Sahlgrenska University Hospital in Gothenburg and the University Hospitals in Uppsala, Lund and Malmö.

The objective for the TASQ project is to develop a pharmaceutical product that can be administered orally for chronic treatment of prostate cancer.

For further information please contact:

Sven Andréasson,

President & CEO

Tel: +46 46 19 20 00

Email: sven.andreasson@activebiotech.com

Or visit www.activebiotech.com